Difference between revisions of "Vorinostat (Zolinza)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf Vorinostat (Zolinza) package insert]</ref><ref...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf Vorinostat (Zolinza) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vorinostat.pdf Vorinostat (Zolinza) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Histone deacetylase (HDAC) inhibitor. Vorinostat inhibits histone deacetylases HDAC1, HDAC2, and HDAC3 (Class I), as well as HDAC6 (Class II). HDACs normally catalyze removal of acetyl groups from acetylated lysine residues in histones and non-histone proteins, which helps to regulate gene expression. Inhibiting HDACs and the consequent accumulation of acetylated histones results in cell cycle arrest and apoptosis of cancer cells.<ref name="insert">[http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf Vorinostat (Zolinza) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vorinostat.pdf Vorinostat (Zolinza) package insert (locally hosted backup)]</ref><ref>[http://www.zolinza.com Zolinza manufacturer's site]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/vorinostat. | + | *[http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_ppi.pdf Vorinostat (Zolinza) manufacturer's patient drug information]<ref>[http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_ppi.pdf Vorinostat (Zolinza) manufacturer's patient drug information]</ref> |
| + | *[http://chemocare.com/bio/vorinostat.asp Vorinostat (Zolinza) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/vorinostat.asp Vorinostat (Zolinza) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/vorinostat-patient-drug-information Vorinostat (Zolinza) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vorinostat-patient-drug-information Vorinostat (Zolinza) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/vorinostat-patient-drug-information Vorinostat (Zolinza) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vorinostat-patient-drug-information Vorinostat (Zolinza) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 03:29, 26 February 2012
General information
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Vorinostat inhibits histone deacetylases HDAC1, HDAC2, and HDAC3 (Class I), as well as HDAC6 (Class II). HDACs normally catalyze removal of acetyl groups from acetylated lysine residues in histones and non-histone proteins, which helps to regulate gene expression. Inhibiting HDACs and the consequent accumulation of acetylated histones results in cell cycle arrest and apoptosis of cancer cells.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Vorinostat (Zolinza) manufacturer's patient drug information[4]
- Vorinostat (Zolinza) patient drug information (Chemocare)[5]
- Vorinostat (Zolinza) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Vorinostat (Zolinza) package insert
- ↑ Vorinostat (Zolinza) package insert (locally hosted backup)
- ↑ Zolinza manufacturer's site
- ↑ Vorinostat (Zolinza) manufacturer's patient drug information
- ↑ Vorinostat (Zolinza) patient drug information (Chemocare)
- ↑ Vorinostat (Zolinza) patient drug information (UpToDate)